Injectable Cellular Composites for Cartilage Engineering
Injectable Cellular Composites for Cartilage Engineering
批准号:
8688900
负责人:
Fred Kurtis Kasper
金额:
$31.44万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-04-01 至 2016-06-30
关键词:
AddressAdultAutologousBone RegenerationCartilageCell TransplantsCellsChemicalsClinicalCoupledCulture MediaDefectDegenerative polyarthritisDoseDrug FormulationsEncapsulatedEngineeringEnvironmentFoundationsGelatinGerm CellsGoalsGrowth FactorHydrogelsImplantIn VitroInjectableInsulin-Like Growth Factor IKineticsMechanicsMesenchymal Stem CellsModelingNatural regenerationNatureOryctolagus cuniculusPainPopulationProcessProgress ReportsResearch Project GrantsStagingStem cell transplantStem cellsTestingTimeTissuesTransforming Growth FactorsTranslationsTransplantationarticular cartilagebonecartilage regenerationcombinatorialdensityexperienceimplantationin vivoin vivo Modelnovelnovel strategiesoligo(poly(ethylene glycol)fumarate)osteochondral tissueosteogenicrepairedscaffoldtissue regeneration
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The ultimate goal of this research project is to develop a novel injectable, bilayered, biodegradable hydrogel composite for the co-delivery of chondrogenic growth factors and mesenchymal stem cells (MSCs) to influence the degree and quality of cartilage tissue regeneration within osteochondral defects. We hypothesize that controlled dual delivery of transforming growth factor-21 (TGF-21) and insulin-like growth factor-1 (IGF-1) using optimal release kinetics and doses will induce chondrogenic differentiation of progenitor cells within the recipient to influence the regeneration of cartilage tissue in an osteochondral defect. Additionally, we hypothesize that the duration of exposure of MSCs to TGF-21 and osteogenic medium supplements during in vitro expansion will modulate the chondrogenic and osteogenic differentiation stages of the cells, respectively, which will in turn influence the degree and quality of osteochondral tissue regeneration when the cells are encapsulated within and transplanted with a hydrogel construct. Finally, we hypothesize that the co-delivery of growth factor(s) from hydrogel composites, coupled with the transplantation of progenitor cells encapsulated within the hydrogels will act cooperatively to promote regeneration of cartilage tissue in an osteochondral defect, with the initial cell seeding density influencing the degree and quality of the cartilage regeneration. To address these hypotheses, three Specific Aims are proposed. First, TGF-21 and IGF-1 will be loaded into OPF hydrogel constructs at different doses and released with different kinetics to determine the effect of these parameters on tissue regeneration in a rabbit osteochondral defect. Second, MSCs will be exposed to TGF-21 as a chondrogenic culture medium supplement or osteogenic medium supplements for various durations to result in cells of different chondrogenic and osteogenic differentiation stages, respectively, then they will be encapsulated within and transplanted with OPF hydrogel scaffolds (without loaded growth factors) into a rabbit osteochondral defect model to assess the effect of the differentiation stages of the transplanted cells upon osteochondral tissue regeneration. Third, cells of the optimal differentiation stages will be encapsulated for transplantation within OPF scaffolds corresponding to the optimal growth factor delivery formulation and will be implanted into rabbit osteochondral defects to determine the optimal seeding density of the progenitor cells for osteochondral tissue regeneration, which will be assessed post-implantation through histomorphometric analysis and mechanical testing. This novel strategy for the concurrent and spatially defined delivery of chondrogenic growth factors and in vitro expanded autologous progenitor cells to osteochondral defects presents tremendous potential for clinical translation and osteochondral tissue regeneration.
期刊论文(61)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Injectable biodegradable hydrogels for embryonic stem cell transplantation: improved cardiac remodelling and function of myocardial infarction.
用于胚胎干细胞移植的可注射生物降解水凝胶:改善心脏重塑和心肌梗塞功能。
DOI:
10.1111/j.1582-4934.2011.01409.x
发表时间:
2012-06
期刊:
Journal of cellular and molecular medicine
影响因子:
5.3
作者:
[Wang H, Liu Z, Li D, Guo X, Kasper FK, Duan C, Zhou J, Mikos AG, Wang C]
通讯作者:
Wang C
DOI:
10.1016/j.biomaterials.2009.01.048
发表时间:
2009-05
期刊:
BIOMATERIALS
影响因子:
14
作者:
[Guo, Xuan, Park, Hansoo, Liu, Guangpeng, Liu, Wei, Cao, Yilin, Tabata, Yasuhiko, Kasper, F. Kurtis, Mikos, Antonios G.]
通讯作者:
Mikos, Antonios G.
DOI:
10.1016/j.actbio.2010.02.046
发表时间:
2010-08
期刊:
ACTA BIOMATERIALIA
影响因子:
9.7
作者:
[Guo, X., Liao, J., Park, H., Saraf, A., Raphael, R. M., Tabata, Y., Kasper, F. K., Mikos, A. G.]
通讯作者:
Mikos, A. G.
Pre-clinical characterization of tissue engineering constructs for bone and cartilage regeneration.
用于骨和软骨再生的组织工程结构的临床前表征。
DOI:
10.1007/s10439-014-1151-0
发表时间:
2015
期刊:
Annals of biomedical engineering
影响因子:
3.8
作者:
[Trachtenberg,JordanE, Vo,TiffanyN, Mikos,AntoniosG]
通讯作者:
Mikos,AntoniosG
DOI:
10.1016/j.actbio.2014.07.011
发表时间:
2014-11
期刊:
ACTA BIOMATERIALIA
影响因子:
9.7
作者:
[Kinard, Lucas A., Dahlin, Rebecca L., Lam, Johnny, Lu, Steven, Lee, Esther J., Kasper, F. Kurtis, Mikos, Antonios G.]
通讯作者:
Mikos, Antonios G.
共 30 条
Three-dimensional Model of Human Ewing Sarcoma
-
批准号:9130807
-
项目类别:
-
资助金额:$32.27万
-
财政年份:2014
-
负责人:Fred Kurtis Kasper
-
依托单位:
Injectable Cellular Composites for Cartilage Engineering
-
批准号:8097545
-
项目类别:
-
资助金额:$32.08万
-
财政年份:2003
-
负责人:Fred Kurtis Kasper
-
依托单位:
Injectable Cellular Composites for Cartilage Engineering
-
批准号:8289677
-
项目类别:
-
资助金额:$32.08万
-
财政年份:2003
-
负责人:Fred Kurtis Kasper
-
依托单位:
Injectable Cellular Composites for Cartilage Engineering
-
批准号:8479209
-
项目类别:
-
资助金额:$30.48万
-
财政年份:2003
-
负责人:Fred Kurtis Kasper
-
依托单位:
Injectable Cellular Composites for Cartilage Engineering
-
批准号:7995060
-
项目类别:
-
资助金额:$33.42万
-
财政年份:2003
-
负责人:Fred Kurtis Kasper
-
依托单位:
海外基金